One Biosciences

The company provides an AI-powered, clinical-grade single-cell profiling platform that analyzes FFPE or frozen samples to create high-quality cellular maps and clinician-ready reports. Their technology is used to accelerate therapeutic development, improve patient selection, and optimize clinical trials across multiple tumor types. The platform specifically targets the precision medicine market by resolving cellular heterogeneity that traditional bulk sequencing cannot capture.